Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years

The article argues that the Vanguard Total International Stock ETF (VXUS) presents a compelling investment opportunity due to a significant valuation gap between international and U.S. stocks. While international stocks have underperformed the S&P 500 by a wide margin over the past decade, they now trade at substantially lower valuations, suggesting potential for outperformance over the next 10 years.

06/20/2026, 6:24 AM • The Motley Fool

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis announced that Rhapsido (remibrutinib) met primary endpoints in the Phase III RemIND trial across three chronic inducible urticaria subtypes, demonstrating twice the symptom control rate versus placebo. The company has submitted an FDA application for the symptomatic dermographism subtype, with additional global regulatory filings planned for 2026. This represents the first targeted therapy for CIndU, addressing an unmet medical need affecting 29 million patients worldwide.

06/12/2026, 5:36 AM • GlobeNewswire

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

Novartis announced that del-brax, an investigational therapy acquired through its $12 billion acquisition of Avidity Biosciences, met primary and key secondary endpoints in a Phase 1/2 study for facioscapulohumeral muscular dystrophy (FSHD). The therapy demonstrated strong target engagement and reduced muscle injury markers, supporting the dosing regimen for the ongoing Phase 3 FORTITUDE-3 trial.

06/11/2026, 9:14 AM • Benzinga

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.

06/10/2026, 1:00 PM • GlobeNewswire

IEFA: Why This Fund Is One of the Best International ETFs

The iShares Core MSCI EAFE ETF (IEFA) is highlighted as one of the best international ETFs, offering diversified exposure to over 2,600 stocks across 16+ developed markets with a low 0.07% expense ratio and 3.30% dividend yield. While it has underperformed the S&P 500 recently, the fund provides valuable portfolio diversification and could serve as a hedge against U.S. market volatility, particularly if tech stocks decline from current valuations.

06/04/2026, 10:30 AM • The Motley Fool

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

Recursion Pharmaceuticals and Schrödinger represent different approaches to AI-driven drug discovery—one biotech-focused with clinical-stage programs, the other software-first with recurring revenue. While both show strong growth (26.9% and 23.3% respectively), Recursion trades at a premium valuation (26.1x P/S) with significant losses and no approved products, while Schrödinger has a lower P/S ratio (4.3x) and improving profitability. The analyst recommends neither stock currently but would choose Schrödinger if forced to pick, citing its established software business and improving financial trajectory.

06/02/2026, 5:12 PM • The Motley Fool

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

06/02/2026, 1:00 PM • GlobeNewswire

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

CRISPR Therapeutics acquired CTX611, a clinical-stage siRNA therapy targeting Factor XI for blood clot prevention, for $95 million upfront. The program could significantly impact the company's revenue despite being a follower in a competitive anticoagulant market dominated by Eliquis and other therapies. With only $1.4 million in Q1 2026 revenue, success with CTX611 could be transformative for the stock.

06/01/2026, 12:30 PM • The Motley Fool

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Novartis announced that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) demonstrated consistent radiographic progression-free survival improvements across key patient subgroups when combined with standard of care in PSMA-positive metastatic hormone-sensitive prostate cancer. The PSMAddition trial showed a 28% reduction in radiographic progression or death risk. Regulatory submissions have been filed in the US, China, and Japan with decisions expected in H2 2026. Additionally, Novartis presented promising Phase 1 data for its actinium-based radioligand therapy 225Ac-PSMA-617, with two Phase 3 trials underway.

05/31/2026, 1:15 AM • GlobeNewswire

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

05/27/2026, 1:00 PM • GlobeNewswire

Worried About Inflation? This International ETF Could Help Protect Your Portfolio

As inflation rises to 3.8% in April, investors are seeking protection strategies. The article recommends dividend stocks and international equities as inflation hedges. The Vanguard International High Dividend Yield ETF (VYMI) is highlighted as a suitable option, offering a 3.47% dividend yield, low 0.07% expense ratio, and strong historical returns of 21% annually over three years.

05/26/2026, 8:30 AM • The Motley Fool

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

05/18/2026, 1:00 PM • GlobeNewswire